Erenumab

Drug Profile

Erenumab

Alternative Names: AMG 334; Anti-CGRP-receptor-monoclonal-antibody-Amgen; Calcitonin gene-related peptide receptor antagonist monoclonal antibody - Amgen; CGRP receptor antagonist monoclonal antibody - Amgen

Latest Information Update: 25 Jun 2017

Price : $50

At a glance

  • Originator Amgen
  • Class Antimigraines; Monoclonal antibodies
  • Mechanism of Action Calcitonin gene-related peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Migraine
  • Phase II Angina pectoris
  • No development reported Hot flashes

Most Recent Events

  • 21 Jun 2017 The European Medicines Agency (EMA) accepts marketing authorisation application (MAA) for erenumab for Migraine for review
  • 31 May 2017 Preregistration for Migraine (Prevention) in European Union (SC)
  • 26 May 2017 Amgen completes an open-label extension phase II trial for Migraine (Prevention) in USA, Canada, Czech Republic, Denmark, Finland, Germany, Norway, Poland, Sweden, United Kingdom (SC) (NCT02174861)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top